MYND Lifesciencs Inc
MYND Life Sciences Inc., a life sciences-based neuro-pharmaceutical drug development company, advances medicines based on neuro-anti-inflammatory substances for depressive disorders through science and clinical trials in Canada and the United States. It focuses on the analysis of psilocin and psilocybin extracts, and analogs. MYND Life Sciences Inc. is based in Port Coquitlam, Canada.
MYND Lifesciencs Inc (MYNDF) - Total Assets
Latest total assets as of July 2024: $719.72K USD
Based on the latest financial reports, MYND Lifesciencs Inc (MYNDF) holds total assets worth $719.72K USD as of July 2024.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
MYND Lifesciencs Inc - Total Assets Trend (2021–2023)
This chart illustrates how MYND Lifesciencs Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
MYND Lifesciencs Inc - Asset Composition Analysis
Current Asset Composition (October 2023)
MYND Lifesciencs Inc's total assets of $719.72K consist of 99.2% current assets and 0.8% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0.0% |
| Accounts Receivable | $776.90K | 97.4% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2021–2023)
This chart illustrates how MYND Lifesciencs Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: MYND Lifesciencs Inc's current assets represent 99.2% of total assets in 2023, an increase from 76.5% in 2021.
- Cash Position: Cash and equivalents constituted 0.0% of total assets in 2023, down from 71.1% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2021.
- Asset Diversification: The largest asset category is accounts receivable at 97.4% of total assets.
MYND Lifesciencs Inc Competitors by Total Assets
Key competitors of MYND Lifesciencs Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
MYND Lifesciencs Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - MYND Lifesciencs Inc generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - MYND Lifesciencs Inc is currently not profitable relative to its asset base.
MYND Lifesciencs Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.09 | 0.00 | 6.02 |
| Quick Ratio | 0.09 | 0.00 | 6.02 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-6.09 Million | $ -5.79 Million | $ 1.37 Million |
MYND Lifesciencs Inc - Advanced Valuation Insights
This section examines the relationship between MYND Lifesciencs Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 0.42 |
| Asset Growth Rate (YoY) | 21.9% |
| Total Assets | $797.54K |
| Market Capitalization | $332.44K USD |
Valuation Analysis
Below Book Valuation: The market values MYND Lifesciencs Inc's assets below their book value (0.42 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: MYND Lifesciencs Inc's assets grew by 21.9% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for MYND Lifesciencs Inc (2021–2023)
The table below shows the annual total assets of MYND Lifesciencs Inc from 2021 to 2023.
| Year | Total Assets | Change |
|---|---|---|
| 2023-10-31 | $797.54K | +21.93% |
| 2022-10-31 | $654.12K | -75.51% |
| 2021-10-31 | $2.67 Million | -- |